AR032466A1 - Ciclilamina sulfonamidas, utilizacion de las mismas para la manufactura de un medicamento y composiciones farmaceuticas utiles como agonistas de los receptores beta-3 adrenergicos - Google Patents

Ciclilamina sulfonamidas, utilizacion de las mismas para la manufactura de un medicamento y composiciones farmaceuticas utiles como agonistas de los receptores beta-3 adrenergicos

Info

Publication number
AR032466A1
AR032466A1 ARP010103379A ARP010103379A AR032466A1 AR 032466 A1 AR032466 A1 AR 032466A1 AR P010103379 A ARP010103379 A AR P010103379A AR P010103379 A ARP010103379 A AR P010103379A AR 032466 A1 AR032466 A1 AR 032466A1
Authority
AR
Argentina
Prior art keywords
alkyl
het
alkyl chain
chain
aryl
Prior art date
Application number
ARP010103379A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR032466A1 publication Critical patent/AR032466A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Ciclilamina sulfonamidas, que comprende un compuesto de la formula (1) en la cual W es (CH2)m; X es (CH2)n; Y es OCH2, SCH2, o un enlace; Z es SO2, CO, o P(O)OR; R es alquilo o arilo; R1 es fenilo sustituido con R4 y R5, o Het sustituido con R4 y R5; R2 es hidrogeno, trifluormetilo, alquilo C1-6, alquenilo de C2 û 7; alquinilo de C2 - 7 o cicloalquilo de C4 - 8 R3 es alquilo de C1 - 6 , alquenilo de C2 - 7 , alquinilo de C2 - 7, cicloalquilo de C4 - 8 , arilo sustituido con R4 y R5, Het sustituido con R4 y R5, ariloxi, -NHCOR7, -NR8R8, arilamino, Het-amino, arilalquilamino que tiene de C1 - 6 en la cadena alquilo, Het-alquilamino que tiene de C1 - 6 en la cadena alquilo, alcoxicarbonilalquilo de C3 - 13 , carboxialquilo de C2 - 7 alquilcarbonilalquilo de C3 - 13 arilcarbonilalquilo que tiene de C1 - 6 en la cadena alquilo, Het-carbonilalquilo que tiene de C1 - 6 en la cadena alquilo, aminocarbonilalquilo de C2 - 7 , alquilamino carbonilalquilo de C3 - 13 , arilaminocarbonilalquilo que tiene de C1 - 6 átomos de carbono en la cadena alquilo, Het-aminocarbonilalquilo que tiene de C1 - 6 en la cadena alquilo, aminosulfonilalquilo de C1 - 6 , alquilsulfonilalquilo de C2 - 12, arilsulfonil alquilo que tiene de C1 - 6 en la cadena alquilo, alquilamino sulfonilalquilo de C2 - 12 , arilaminosulfonilamino que tiene de C1 - 5 en la cadena alquilo, Het-aminosulfonilalquilo que tiene de C1 - 6 en la cadena alquilo, fosfonoalquilo de C1 - 6 , fosforilalquilo de C1-6; R4 y R5, cada uno de ellos e independientemente entre si, hidrogeno, trifluormetilo, alquilo de C1-6, alquenilo de C2-7, alquinilo de C2-7, cicloalquilo de C4-8, arilo, Het, arilalquilo que tiene de C1-6 en la cadena alquilo, Het-alquilo que tiene de C1-6 en la cadena alquilo, halogeno, ciano, nitro, hidroxi, alcoxi, de C1-6 ariloxi, arilalquil oxi que tiene de C1-6 en la cadena alquilo, alquiltio que tiene de C1-6, ariltio, arilamino, Het-amino, arilalquilamino de C1-6en la cadena alquilo, Het-alquilamino que tiene de C1-6 en la cadena alquilo, hidroxi amino, -NHCOR7, -NHSO2R7, -NHP(O)(R7)2, -COR8, -SO2R8, -NR8R8, carboxi, alquil carbonilo de C2-7, fosforilo, alcoxicarbonilalquilo de C3-13 , carboxialquil de C2-7, alquilcarbonil alquilo de C2-13 , arilcarbonilalquilo que tiene de C1-6 en la cadena alquilo, Het-carbonilalquilo que tiene de C1-6 en la cadena alquilo, aminocarbonilalquilo de C2 û 7, alquilaminocarbonilalquilo de C3-13 arilaminocarbonilalquilo que tiene de C1-6 en la cadena alquilo, Het-aminocarbonilaquilo que tiene de C1-6 en la cadena alquilo, aminosulfonil alquilo de C1-6, alquilsulfonilalquilo de C2-12, arilsulfonilalquilo que tiene de C1-6 en la cadena alquilo, alquilaminosulfonilalquilo de C2-12. Arilaminosulfonil alquilo de C1-6, Het-aminosulfonilalquilo de C1-6, fosfonoalquil de C1-6, o fosforilalquilo de C1-6; R7 es hidrogeno, trifluormetilo, alquilo de C1-6, cicloalquilo de C4-8, alquenilo de C2-7, alquinilo de C2-7, arilo, alcoxi de C1-6, NR8R9, o ûNR9(CH2)p-R8, R8 es hidrogeno, alcoxi de C1-6, hidroxi, -(CH2)p-COR9, o (CH2)p-R9; R9 es hidrogeno, hidroxi, alquilo de C1-6, alcoxi de C1-6 o ûNR10R10; R10 es hidrogeno, alquilo de C1-6 átomos de carbono, arilo o Het; Het es un heterociclo monocíclico, o bicíclico de 5 a 10 átomos de anillo, que tiene de 1 a 4 heteroátomos seleccionados de entre el grupo consistente en oxígeno, nitrogeno, y azufre, pudiendo el heterociclo estar saturado, no saturado, parcialmente no saturado y puede estar opcionalmente fusionado a un anillo fenilo; m es de 1 a 3; n es de 1 a 3; p es de 0 a 6; o una sal farmacéuticamente aceptable de los mismos; utilizacion de las mismas para la manufactura de un medicamento y composiciones farmacéuticas utiles, en el tratamiento de los trastornos metabolicos relacionados con la resistencia contra la insulina o con la hiperglicemia.
ARP010103379A 2000-07-17 2001-07-16 Ciclilamina sulfonamidas, utilizacion de las mismas para la manufactura de un medicamento y composiciones farmaceuticas utiles como agonistas de los receptores beta-3 adrenergicos AR032466A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21876400P 2000-07-17 2000-07-17

Publications (1)

Publication Number Publication Date
AR032466A1 true AR032466A1 (es) 2003-11-12

Family

ID=22816416

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103379A AR032466A1 (es) 2000-07-17 2001-07-16 Ciclilamina sulfonamidas, utilizacion de las mismas para la manufactura de un medicamento y composiciones farmaceuticas utiles como agonistas de los receptores beta-3 adrenergicos

Country Status (10)

Country Link
US (2) US6498170B2 (es)
EP (1) EP1328512A2 (es)
JP (1) JP2004504296A (es)
CN (1) CN1455769A (es)
AR (1) AR032466A1 (es)
AU (1) AU2002222929A1 (es)
BR (1) BR0112582A (es)
CA (1) CA2416667A1 (es)
MX (1) MXPA03000450A (es)
WO (1) WO2002006221A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2326777C (en) * 1998-04-01 2011-12-20 Nortran Pharmaceuticals Inc. Aminocyclohexyl ether compounds and uses thereof
US6979685B1 (en) * 1999-02-12 2005-12-27 Cardiome Pharma Corp. Cycloalkyl amine compounds and uses thereof
US7507545B2 (en) 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
US6410734B1 (en) * 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US7057053B2 (en) * 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7524879B2 (en) * 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US6376514B1 (en) * 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) * 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6885903B2 (en) * 2001-07-10 2005-04-26 General Electric Company Method and system for tracking repair of components
US6856733B2 (en) * 2001-12-07 2005-02-15 Intel Corporation 1xN fanout waveguide photodetector
US7345086B2 (en) * 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
BRPI0318278B8 (pt) * 2003-05-02 2024-01-09 Cardiome Pharma Corp Compostos de éter aminocicloexílico, composição compreendendo ditos compostos, usos dos mesmos e método para modular a atividade do canal iônico em um ambiente in vitro
US20090041841A1 (en) * 2003-05-02 2009-02-12 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
US7674820B2 (en) * 2003-08-07 2010-03-09 Cardiome Pharma Corp. Ion channel modulating activity I
US7345087B2 (en) * 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
CA2561819A1 (en) 2004-04-01 2005-12-01 Cardiome Pharma Corp. Prodrugs of ion channel modulating compounds and uses thereof
WO2005097087A2 (en) * 2004-04-01 2005-10-20 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
US7572792B2 (en) * 2004-04-29 2009-08-11 Merck & Co., Inc. Azetidine glycine transporter inhibitors
JP5583325B2 (ja) * 2004-11-08 2014-09-03 カーディオム ファーマ コーポレイション イオンチャネル調節化合物の投与レジメ
US20070054590A1 (en) * 2005-08-24 2007-03-08 Schmidt Christopher B Photo-chromic toys
JP5114202B2 (ja) 2005-09-27 2013-01-09 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するスルホンアミド誘導体
BRPI0617364A2 (pt) 2005-10-13 2011-07-26 Orchid Res Lab Ltd compostos heterocÍclicos como inibidores de pstat3/il-6
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
WO2011025690A1 (en) * 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348393A (en) 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
US4775670A (en) * 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
EP0089154A3 (en) 1982-03-12 1984-08-08 Beecham Group Plc Ethanolamine derivatives, their preparation and use in pharmaceutical compositions
US4499100A (en) * 1983-05-18 1985-02-12 Syntex (U.S.A.) Inc. Benzodioxanyl-hydroxyethyleneamino-piperidinyl acetanilides, ketones, esters and carbamates which effect immunity and calcium entry and β-blockade
GB2163150B (en) 1984-07-19 1988-05-25 Sandoz Ltd 3-aminopropoxyaryl derivatives
GB8528633D0 (en) 1985-11-21 1985-12-24 Beecham Group Plc Compounds
US4813998A (en) 1986-02-27 1989-03-21 Janssen Pharmaceutica N.V. Herbicidal 1H-imidazole-5-carboxylic acid derivatives
EP0449261A3 (en) 1990-03-29 1992-02-26 Kabushiki Kaisha Toshiba Resin composition for an optical disc and an optical disc using it
ZA936324B (en) 1992-08-31 1994-03-22 Sankyo Co Oxazolidine derivatives having anti-diabetic and anti-obesity properties their preparation and their therapeutic uses
US5998452A (en) 1993-06-23 1999-12-07 Chugai Seiyaku Kabushiki Kaisha Benzene derivatives, compositions and methods for treating ischemic diseases
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
CA2145257A1 (en) 1994-03-23 1995-09-24 Takashi Fujita Thiazolidine and oxazolidine derivatives, their preparation and their medical use
US5561142A (en) 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
IL113410A (en) * 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5614523A (en) 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5789402A (en) 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
US5741789A (en) 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
ATE239694T1 (de) * 1995-10-26 2003-05-15 Mitsubishi Pharma Corp Phenylethanolamin-verbindungen und ihre anwendung als beta3 agonisten, verfahren zu ihrer herstellung und zwischenprodukte ihrer herstellung
EP0801060A1 (en) * 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
AU712057B2 (en) * 1996-06-07 1999-10-28 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity
AU2995497A (en) 1996-07-26 1997-11-19 Dr. Reddy's Research Foundation Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
EP0827746B1 (en) 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
WO1998022480A1 (en) * 1996-11-18 1998-05-28 Smithkline Beecham Plc Phosphorus containing aryloxy or arylthio propanolamine derivatives
BR9807096A (pt) * 1997-01-28 2000-04-18 Merck & Co Inc Composto, processos para o tratamento do diabetes, da obesidade em um mamìfero, para reduzir nìveis de triglicerìdeos e nìveis de colesterol ou elevar nìveis de lipoproteìnas de alta densidade, para diminuir a motilidade do intestino, para reduzir inflamação neurogênica das vias aéreas e a depressão e para tratar distúrbios gastrintestinais, e, composições para o tratamento dos distúrbios acima e farmacêutica
US6150378A (en) 1997-10-07 2000-11-21 Cephalon, Inc. Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors
US6346532B1 (en) 1997-10-17 2002-02-12 Yamanouchi Pharmaceutical Co., Ltd. Amide derivatives or salts thereof
FR2780057B1 (fr) 1998-06-18 2002-09-13 Sanofi Sa Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
US6214842B1 (en) 1999-05-12 2001-04-10 Michael S. Malamas Amino-thiazolidinediones useful in the treatment of insulin resistance and hyperglycemia
FR2798126B1 (fr) 1999-09-08 2001-10-19 Sanofi Synthelabo Heteroaryloxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2802533B1 (fr) 1999-12-17 2002-02-15 Sanofi Synthelabo Phenoxypropanolamines, leur preparation et leur application en therapeutique
AU2525801A (en) 1999-12-17 2001-06-25 Sanofi-Synthelabo Phenoxypropanolamines, method for producing them and pharmaceutical compositionscontaining them
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6509358B2 (en) 2000-07-17 2003-01-21 Wyeth Piperidino-phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US6410734B1 (en) 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6514991B2 (en) 2000-07-17 2003-02-04 Wyeth Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
US6395762B1 (en) 2000-07-17 2002-05-28 American Home Products Corporation Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6458817B1 (en) 2000-07-17 2002-10-01 Wyeth Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists

Also Published As

Publication number Publication date
CA2416667A1 (en) 2002-01-24
EP1328512A2 (en) 2003-07-23
US20030027797A1 (en) 2003-02-06
WO2002006221A3 (en) 2002-06-13
JP2004504296A (ja) 2004-02-12
US20020022605A1 (en) 2002-02-21
BR0112582A (pt) 2003-05-20
US6498170B2 (en) 2002-12-24
AU2002222929A1 (en) 2002-01-30
WO2002006221A2 (en) 2002-01-24
CN1455769A (zh) 2003-11-12
MXPA03000450A (es) 2003-06-06
US6649603B2 (en) 2003-11-18

Similar Documents

Publication Publication Date Title
AR032466A1 (es) Ciclilamina sulfonamidas, utilizacion de las mismas para la manufactura de un medicamento y composiciones farmaceuticas utiles como agonistas de los receptores beta-3 adrenergicos
PE20090641A1 (es) Amidas heterociclicas
AR020851A2 (es) Compuestos macrolidos, composiciones y su uso para la preparacion de medicamentos
PE20090042A1 (es) Analogos de ciclopamina
PE20061163A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos
AR069412A1 (es) Derivados de pirimidina, proceso para prepararlos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades virales, bacterianas y alergicas, entre otras.
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
HUP0203836A2 (hu) 1,3-Diszubsztituált pirrolidin-származékok alfa2-adrenerg-receptor antagonista hatással, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
PE20081493A1 (es) Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
PE20070108A1 (es) Control de parasitos en animales con derivados de n-[(feniloxi)fenil]-1,1,1-trifluorometansulfonamida y de n-[(fenilsulfanil)fenil]-1,1,1-trifluorometansulfonamida
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
AR048641A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame
PE20020544A1 (es) Derivados de indolilmaleimida
AR019790A2 (es) Compuestos derivados de la eritromicina, composiciones que los contienen. uso para preparar un medicamento
CO5070570A1 (es) DERIVADOS DE TIROSINA COMO ACTIVADORES DE hPPAR Y hPPARalfa Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE
PE20060693A1 (es) Nuevos derivados de trifluorometansulfonanilida oxamida eter
PE20051136A1 (es) Derivados de sulfonamida
PE20020566A1 (es) DERIVADOS DE FENILACETAMIDO-PIRAZOLES COMO INHIBIDORES DE LA cdk/CICLINA QUINASA
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2213007T3 (es) Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2.
PE20050484A1 (es) Composicion farmaceutica de liberacion sostenida
AR029821A1 (es) Decahidro-isoquinolinas, un proceso para su preparacion, composiciones farmaceuticas que las comprenden y el uso de las mismas para la fabricacion de un medicamento
AR057005A1 (es) Derivados de 4-fenil-5-oxo-1,4,5,6,7,8-hexahidroquinolina, una composicion farmaceutica y uso del compuesto para preparar un medicamento
PE20021018A1 (es) DERIVADOS DE ß - CARBOLINA

Legal Events

Date Code Title Description
FB Suspension of granting procedure